The overall objective is to investigate to investigate how safe, how well tolerated, and how effective R3R01 is in treating uncontrolled proteinuria in patients with Alport syndrome and steroid-resistant Focal Segmental Glomerulosclerosis. All eligible participants will be enrolled to receive R3R01 over a treatment period of 12 weeks. The study will consist of 3 periods, including a screening period of 3 weeks, a treatment period of 12 weeks, and a follow up of period of 12 weeks.
You may be eligible to participate if: • You are aged 18 years or older • Female patients and female partners of male patients willing to not become pregnant for the duration of the study • Have not had an organ transplant and/or on a organ transplant list • Have high protein in urine Alport Syndrome (AS) specific: • Have X-linked AS and autosomal recessive AS • Confirmed diagnosis of AS be genetic testing or kidney biopsy • Do not have another kidney disease FSGS specific: • Not older than 75 years of age • Primary Focal segmental glomerulosclerosis (FSGS) (not caused by other condition) that is confirmed by kidney biopsy or documentation of genetic mutation • Steroid-resistance: previous steroid treatment without remission
The purpose of the study is to learn about how African immigrants make decisions about childbearing, both individually and as a couple, the role of modern contraception in helping them achieve their fertility desires and the effect of migration on their childbearing desires.
- Nigerian immigrant men and women of reproductive age (18-45 years) and,
- Are in a relationship (dating, engaged or married)
The purpose of this study is to explore the physicians’ knowledge of intellectual disabilities (ID) and their medical training and practice. The information resulting from this study will help to design adequate interventions and training programs for medical students and physicians aimed to improve their ID knowledge and the health care services provided to patients with ID. This is an observational cross-sectional study of physicians in the US using an anonymous online survey. The entire survey has 156 items and will require 15-20 minutes to complete.
- You are an American medical resident, an attending physician, or a medical educator in any type of medical specialization, and - You have or do not have experience with patients with intellectual disabilities
This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.
Participants must meet the following criteria:
- Native English speaker
- Able to have an MRI
- Had only one stroke (in the left hemisphere of the brain)
Evaluate factors that influence African American women’s healthy lifestyle behaviors and beliefs. A descriptive study using anonymous survey data.
Adult African American/Black women
The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent training, on parent-teen communications as well as teens' risky driving behaviors, unsafe driving behaviors, and subsequent traffic violations.
In order to be eligible:
- You must be 16 -18 years of age
- Need a valid State of Ohio driver's license (no learner's permit)
- Proof of car insurance
- Must drive more than one hour per week
The purpose of this study is to see how laughing gas (nitrous oxide) changes brain activity in study participants with and without “anger issues”. Brain activity is measured by Magnetic Resonance Imaging.
The length of time you will be involved in this study will be 4-8 weeks.
- You are a medically healthy man or woman
- You are between the ages of 21 and 55 years of age
- Do not abuse alcohol or other drugs
- With a current history of “anger issues”
- Able to complete study sessions during the week
This study looks at what is helping people adjust to the changes caused by the COVID-19 pandemic so that we may understand what could help people adapt to crises in the future. This information could benefit with the understanding and improvement of treatments for conditions such as depression and anxiety.
The study will examine the experience of psychological symptoms, adaptability, and coping over time.
You may eligible for this study if you are:
• 18 years of age or older
• Currently unemployed or laid off
• Be considered high risk if infected with COVID-19 (e.g., being 65 or older or having an underlying health condition).
• Have NOT had a positive COVID-19 test result
• Do NOT have an immunity to COVID-19
To explore how parents make the decision on transitioning their children from booster seats to seat belts; what factors may influence parents’ decision on the transition.
Inclusion criteria: o At least 18 years of age o A parent or legal guardian who is responsible for transporting their child routinely o Have a child stopped using booster seats within 1 year prior to the interview date, and the child who made the transition must be the first child of the parent o Drive with a child at least once per week o In good general health o Fluent in English.
The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) versus dupilumab for the treatment of adult subjects (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Subject must have chronic Atopic Dermatitis (AD) with onset at least 3 years prior to study participation - Subject must have > or = 10% body surface area involvement of atopic dermatitis - Subject must have had inadequate response to topical corticosteroids or topical calcineurin inhibitors within the past 6 months - OR documented systemic treatment for AD within the past 6 months - OR for whom topical treatments are otherwise medically inadvisable - No prior exposure to any JAK inhibitor ( eg. ruxolitinib, tofacitinib, baricitinib, upadacitinib, PF-04965842, and filgotinib) - No prior exposure to dupilumab